SEC Company Response from Black Diamond Therapeutics, (BDTX) — Dec 1, 2025
Black Diamond Therapeutics, Inc.
Date: Dec. 1, 2025 · CIK: 0001701541 · Accession: 0001104659-25-117310
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291518
Letter
Re: Black Diamond Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed on November 13, 2025
VIA EDGAR
December 1, 2025
United States Securities and Exchange Commission
Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Attention: Jason Drory
File No. 333-291518
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Black Diamond Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to December 3, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072. If you have any questions regarding this request, please contact Adam V. Johnson.
Sincerely,
BLACK DIAMOND THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm VIA EDGAR December 1, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Black Diamond Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed on November 13, 2025 File No. 333-291518 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Black Diamond Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to December 3, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072. If you have any questions regarding this request, please contact Adam V. Johnson. Sincerely, BLACK DIAMOND THERAPEUTICS, INC. /s/ Mark A. Velleca Mark A. Velleca President and Chief Executive Officer cc: Brent Hatzis-Schoch, Esq., Black Diamond Therapeutics, Inc. Erika Jones, Black Diamond Therapeutics, Inc. Robert E. Puopolo, Esq., Goodwin Procter LLP Adam V. Johnson, Esq., Goodwin Procter LLP